



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/39, C12N 5/06, 5/08, A61K 39/00, 35/14, C07K 14/705, C12N 15/12, C07K 16/28, G01N 33/50, A61P 37/04, 37/06 // C07K 19/00		A2	(11) International Publication Number: WO 00/48631 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/GB00/00559 (22) International Filing Date: 17 February 2000 (17.02.00) (30) Priority Data: 9903664.2 17 February 1999 (17.02.99) GB (71) Applicant (for all designated States except US): ISIS INNOVATION LIMITED [GB/GB]; Ewert House, Ewert Place, Summertown, Oxford OX2 7BZ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): MACPHERSON, George, Gordon [GB/GB]; University of Oxford, Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE (GB). WYKES, Michelle, Niloufer [AU/AU]; Mater Medical Research Institute, Level 3 Aubigny Place, Raymond Terrace, South Brisbane, QLD 4152 (AU). (74) Agents: IRVINE, Jonquil, Claire et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: ADJUVANT AND CELL MATURATION AGENT			
(57) Abstract Use of CD38, or a portion thereof or analogue thereof which can inhibit the binding of CD38 to a non-follicular dendritic cell (DC) or a follicular dendritic cell (FDC) and which retains the ability of CD38 to stimulate a DC or FDC, for use in the manufacture of an adjuvant for use in immunotherapy. Also provided is a method of maturing DCs <i>in vitro</i> and a vaccine comprising mature DCs. The invention also provides a natural ligand of CD38 on FDCs and DCs and inhibitors of the ligand. The inhibitors can be used for immunosuppression.			